Company Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Brian M. Strem Ph.D. |
Contact Details
Address: 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 United States | |
| Phone | 781-788-8869 |
| Website | kiorapharma.com |
Stock Details
| Ticker Symbol | KPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372514 |
| CUSIP Number | 49721T101 |
| ISIN Number | US49721T3095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian M. Strem Ph.D. | President, Chief Executive Officer and Director |
| Melissa Tosca CPA | Executive Vice President of Finance |
| Dr. Eric J. Daniels M.B.A., M.D. | Chief Development Officer |
| Dr. Stefan Sperl Ph.D. | Executive Vice President of CMC and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | EFFECT | Notice of Effectiveness |
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 25, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 15, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |